NEW YORK (GenomeWeb) - Biocept today after the close of the market reported a 300 percent increase year over year in its fourth quarter revenues.

For the three months ended Dec. 31, 2014, Biocept's total revenues increased to $76,000 from $19,000 in the prior-year fourth quarter, primarily related to higher commercial test volume, the firm said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.